DrugPatentWatch Database Preview
ROCKLATAN Drug Profile
When do Rocklatan patents expire, and what generic alternatives are available?
Rocklatan is a drug marketed by Aerie Pharms Inc and is included in one NDA. There are seven patents protecting this drug.
This drug has forty-three patent family members in seven countries.
The generic ingredient in ROCKLATAN is latanoprost; netarsudil dimesylate. There are twenty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the latanoprost; netarsudil dimesylate profile page.
Summary for ROCKLATAN
| International Patents: | 43 |
| US Patents: | 7 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for ROCKLATAN |
| DailyMed Link: | ROCKLATAN at DailyMed |
Generic Entry Opportunity Date for ROCKLATAN
Generic Entry Date for ROCKLATAN*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION/DROPS;OPHTHALMIC |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for ROCKLATAN
| Drug Class | Rho Kinase Inhibitor Prostaglandin Analog |
| Mechanism of Action | Rho Kinase Inhibitors |
US Patents and Regulatory Information for ROCKLATAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aerie Pharms Inc | ROCKLATAN | latanoprost; netarsudil dimesylate | SOLUTION/DROPS;OPHTHALMIC | 208259-001 | Mar 12, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Aerie Pharms Inc | ROCKLATAN | latanoprost; netarsudil dimesylate | SOLUTION/DROPS;OPHTHALMIC | 208259-001 | Mar 12, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Aerie Pharms Inc | ROCKLATAN | latanoprost; netarsudil dimesylate | SOLUTION/DROPS;OPHTHALMIC | 208259-001 | Mar 12, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ROCKLATAN
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2018202990 | Start Trial |
| Japan | 6141385 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2014144781 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ROCKLATAN
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0364417 | 97C0128 | France | Start Trial | PRODUCT NAME: LATANOPROST; REGISTRATION NO/DATE IN FRANCE: NL 22549 DU 19970724; REGISTRATION NO/DATE AT EEC: 12716 DU 19960718 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
